Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitorPhilipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D ResultsMazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood|December 24, 2023
Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuriaRichard J Kelly, Matthew Holt, Jennifer Vidler, et al.
Blood Advances|December 18, 2024
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response ratesAna Rita da Fonseca, Caio Cesar Justino, Vinicius Campos de Molla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2019
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY StudyPeter Hillmen, Andy C Rawstron, Kristian Brock, et al.
Blood|June 30, 2023
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trialJohn F Seymour, John C Byrd, Paolo Ghia, et al.
NEJM Evidence|February 6, 2024
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesArnon P Kater, Carolyn Owen, Carol Moreno, et al.
Blood Advances|March 31, 2026
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemiaRichard R Furman, William G Wierda, Piers Em Patten, et al.
Blood Advances|August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studiesConstantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
Pageof 7